Soligenix, Inc. (LON:0A6I)
2.360
-0.065 (-2.70%)
At close: Feb 18, 2025
Soligenix Revenue
Soligenix had revenue of $364.18K USD in the twelve months ending September 30, 2024, down -62.09% year-over-year. In the year 2023, Soligenix had annual revenue of $839.36K, down -11.55%.
Revenue (ttm)
$364.18K
Revenue Growth
-62.09%
P/S Ratio
n/a
Revenue / Employee
$24.28K
Employees
15
Market Cap
4.82M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
Dec 31, 2019 | 4.63M | -611.53K | -11.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
Shell | 227.10B |
HSBC Holdings | 48.93B |
Unilever | 50.25B |
Rio Tinto Group | 42.86B |
RELX PLC | 9.43B |
BP p.l.c. | 149.68B |
British American Tobacco p.l.c. | 25.87B |
Soligenix News
- 19 days ago - Soligenix to Present at BIO CEO & Investor Conference - PRNewsWire
- 5 weeks ago - Soligenix to Present at Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - Benzinga
- 5 weeks ago - HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer - Benzinga
- 2 months ago - HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - PRNewsWire
- 3 months ago - Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire